DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Acelyrin - 1 Acelyrin's izokibep - 1 Hidradenitis - 1 Piper Sandler - 1 Jefferies - 1 Akash Tewari - 1 We'll - 1 Christy Santhosh - 1
Top related locs:
Bengaluru Acelyrin New York U.S Cava United States
Top related orgs:
Thomson - 3 New York Stock Exchange - 2 Ventyx Biosciences - 1 Apogee Therapeutics - 1 REUTERS - 1 Kappa - 1 Dow - 1 Nasdaq - 1

Search resuls for: "Acelyrin"


4 mentions found


☆ Acelyrin's skin disease drug trial failure wipes off IPO gains
  + stars: | 2023-09-12 | by ( Christy Santhosh | ) www.reuters.com   time to read: +2 min
Sept 12 (Reuters) - Shares of drug developer Acelyrin (SLRN.O) on Tuesday erased all gains made since their stellar market debut in May, as the company's experimental lead drug failed to show superiority to placebo in reducing symptoms of an inflammatory skin disease. HS is a chronic inflammatory skin condition that causes painful lumps under the skin. Acelyrin said the trial was hit by early discontinuations as well as better placebo efficacy rates. However, Jefferies analyst Akash Tewari slashed the price target on Acelyrin's stock to $15 from $31, calling the latest data "painfully disappointing." "It's difficult to glean much from the data given how poorly the trial was run.
Persons: Acelyrin, Acelyrin's izokibep, Hidradenitis, Piper Sandler, Jefferies, Akash Tewari, We'll, Christy Santhosh, Saumyadeb Chakrabarty Organizations: Ventyx Biosciences, Apogee Therapeutics, Thomson Locations: Acelyrin, Bengaluru
☆ Futures dip as investors await key inflation data
  + stars: | 2023-09-12 | by ( Ankika Biswas Shristi Achar A | Ankika Biswas | Shristi Achar A | ) www.reuters.com   time to read: +3 min
A Wall Street sign is pictured outside the New York Stock Exchange in New York, October 28, 2013. Investors await August consumer prices data, due on Wednesday, and producer prices scheduled on Thursday, followed by the Fed's policy decision on Sept. 20. A recent uptick in oil prices and strong economic data have fueled concerns over stubborn inflation, clouding the outlook for an end to U.S. monetary tightening. Investors will also monitor the European Central Bank's policy decision on Thursday, where it is seen holding rates after nine consecutive hikes. ET, Dow e-minis were down 48 points, or 0.14%, S&P 500 e-minis were down 9 points, or 0.2%, and Nasdaq 100 e-minis were down 27.5 points, or 0.18%.
Persons: Carlo Allegri, Wall, Morgan Stanley, BoE, Mohit Kumar, Ankika Biswas, Shristi, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Kappa, Dow, Nasdaq, Microsoft, Investors, Fed, ECB, Jefferies, Dow e, Oracle, Paramount Global, Amusements, Thomson Locations: New York, U.S, Bengaluru
☆ Restaurant chain Cava raises IPO valuation target to $2.23 bln
  + stars: | 2023-06-12 | by ( ) www.reuters.com   time to read: +1 min
June 12 (Reuters) - Cava Group Inc, which operates a chain of Mediterranean fast-casual restaurants in the United States, said on Monday that it is now aiming for a valuation of up to $2.23 billion in its U.S. initial public offering. Cava now intends to sell roughly 14.44 mln shares to raise $289 million based on the top end of the new proposed range, up from $274.4 million last week. The company is expected to debut on the New York Stock Exchange under the symbol "CAVA" on Thursday. Cava logged a net loss of $59 million in fiscal 2022 compared to $37.4 million in the prior year. Reporting by Manya Saini and Savyata Mishra in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
Persons: Manya Saini, Savyata Mishra, Shailesh Organizations: Inc, New York Stock Exchange, Cava, Thomson Locations: Cava, United States, Bengaluru
☆ Biopharma firm Acelyrin valued at $2.1 billion in strong market debut
  + stars: | 2023-05-05 | by ( ) www.reuters.com   time to read: +1 min
May 5 (Reuters) - Shares of Acelyrin Inc (SLRN.O) rose 28% in their Nasdaq debut on Friday, giving the biopharma company a market capitalization of $2.1 billion. The Los Angeles-based company, which had priced its shares at $18 apiece, raised $540 million by selling 30 million shares in an upsized offering on Thursday. Acelyrin joins a spate of new listings recently that have fueled hopes of a recovery in IPO markets. On Thursday, Johnson & Johnson Inc's (JNJ.N) consumer health business Kenvue Inc (KVUE.N) went public, becoming the largest public offering since Rivian Automotive Inc (RIVN.O) in 2021. Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 4